CanSino Biotech, an innovative biopharmaceutical company, completed its Star market IPO on 13 August.
The company had filed its application for the listing in January, in accordance with the fifth set of listing standards, which allows the listing of pre-revenue companies.
You must be a
subscribersubscribersubscribersubscriber
to read this content, please
subscribesubscribesubscribesubscribe
today.
For group subscribers, please click here to access.
Interested in group subscription? Please contact us.
你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章，欢迎成为我们的订阅会员成为我们的订阅会员。
